GIP-derived GIP receptor antagonists - a review of their role in GIP receptor pharmacology.
GIP
Obesity
antagonist
co-agonist
diabetes
incretin
pharmacology
Journal
Peptides
ISSN: 1873-5169
Titre abrégé: Peptides
Pays: United States
ID NLM: 8008690
Informations de publication
Date de publication:
10 Apr 2024
10 Apr 2024
Historique:
received:
03
02
2024
revised:
01
04
2024
accepted:
08
04
2024
medline:
13
4
2024
pubmed:
13
4
2024
entrez:
12
4
2024
Statut:
aheadofprint
Résumé
Surprisingly, agonists, as well as antagonists of the glucose-dependent insulinotropic polypeptide receptor (GIPR), are currently being used or investigated as treatment options for type 2 diabetes and obesity - and both, when combined with glucagon-like peptide 1 receptor (GLP-1R) agonism, enhance GLP-1-induced glycemia and weight loss further. This paradox raises several questions regarding not only the mechanisms of actions of GIP but also the processes engaged during the activation of both the GIP and GLP-1 receptors. Here, we provide an overview of studies of the properties and actions of peptide-derived GIPR antagonists, focusing on GIP(3-30)NH
Identifiants
pubmed: 38608836
pii: S0196-9781(24)00065-2
doi: 10.1016/j.peptides.2024.171212
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
171212Informations de copyright
Copyright © 2024. Published by Elsevier Inc.